Shin Poong Pharm.Co.,Ltd. (019170.KS)
KRW 10370.0
(-5.04%)
KRW 10370.0
(-5.04%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -47.39 Billion KRW | -43.97% |
| 2022 | -34.01 Billion KRW | -276.11% |
| 2021 | -9.04 Billion KRW | -179.7% |
| 2020 | 11.34 Billion KRW | 34.71% |
| 2019 | 8.42 Billion KRW | -21.16% |
| 2018 | 10.68 Billion KRW | 36.74% |
| 2017 | 7.81 Billion KRW | -18.33% |
| 2016 | 9.56 Billion KRW | 125.91% |
| 2015 | 4.23 Billion KRW | -78.0% |
| 2014 | 19.25 Billion KRW | -22.41% |
| 2013 | 24.81 Billion KRW | 2.38% |
| 2012 | 24.23 Billion KRW | -36.72% |
| 2011 | 38.29 Billion KRW | -12.91% |
| 2010 | 43.97 Billion KRW | 24.69% |
| 2009 | 35.26 Billion KRW | 12.9% |
| 2008 | 31.23 Billion KRW | 62.88% |
| 2007 | 19.17 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.79 Billion KRW | 90.55% |
| 2024 Q1 | -4.2 Billion KRW | 73.41% |
| 2023 Q1 | -11.61 Billion KRW | -20.22% |
| 2023 Q2 | -9.69 Billion KRW | 16.52% |
| 2023 Q4 | -15.83 Billion KRW | -45.56% |
| 2023 Q3 | -10.87 Billion KRW | -12.16% |
| 2023 FY | -48.97 Billion KRW | -43.97% |
| 2022 Q2 | -2.84 Billion KRW | 59.23% |
| 2022 Q4 | -9.66 Billion KRW | 31.93% |
| 2022 FY | -34.01 Billion KRW | -276.11% |
| 2022 Q3 | -14.19 Billion KRW | -399.07% |
| 2022 Q1 | -6.97 Billion KRW | 18.82% |
| 2021 Q1 | 1.11 Billion KRW | -43.47% |
| 2021 Q2 | -1.1 Billion KRW | -199.34% |
| 2021 Q3 | -5.72 Billion KRW | -416.34% |
| 2021 Q4 | -8.59 Billion KRW | -50.21% |
| 2021 FY | -9.04 Billion KRW | -179.7% |
| 2020 Q4 | 1.97 Billion KRW | 50.85% |
| 2020 Q1 | 2.06 Billion KRW | 276.77% |
| 2020 FY | 11.34 Billion KRW | 34.71% |
| 2020 Q3 | 1.3 Billion KRW | -47.62% |
| 2020 Q2 | 2.49 Billion KRW | 20.76% |
| 2019 Q3 | 4.1 Billion KRW | 262.63% |
| 2019 Q2 | 1.13 Billion KRW | -26.42% |
| 2019 Q1 | 1.53 Billion KRW | 12.16% |
| 2019 Q4 | -1.16 Billion KRW | -128.51% |
| 2019 FY | 8.42 Billion KRW | -21.16% |
| 2018 Q4 | 1.37 Billion KRW | -47.7% |
| 2018 FY | 10.68 Billion KRW | 36.74% |
| 2018 Q3 | 2.62 Billion KRW | 3.98% |
| 2018 Q2 | 2.52 Billion KRW | 103.45% |
| 2018 Q1 | 1.23 Billion KRW | 157.13% |
| 2017 Q2 | 4.12 Billion KRW | 29.06% |
| 2017 Q1 | 3.19 Billion KRW | -23.95% |
| 2017 FY | 7.81 Billion KRW | -18.33% |
| 2017 Q4 | -2.16 Billion KRW | -181.3% |
| 2017 Q3 | 2.66 Billion KRW | -35.29% |
| 2016 Q3 | 2.09 Billion KRW | 112.32% |
| 2016 Q4 | 4.19 Billion KRW | 100.75% |
| 2016 Q1 | 2.29 Billion KRW | -13.59% |
| 2016 FY | 9.56 Billion KRW | 125.91% |
| 2016 Q2 | 985.33 Million KRW | -57.0% |
| 2015 FY | 4.23 Billion KRW | -78.0% |
| 2015 Q1 | 1.75 Billion KRW | -10.31% |
| 2015 Q4 | 2.65 Billion KRW | 265.76% |
| 2015 Q3 | 724.95 Million KRW | 181.27% |
| 2015 Q2 | -892.02 Million KRW | -150.94% |
| 2014 Q4 | 1.95 Billion KRW | -73.43% |
| 2014 Q1 | 4 Billion KRW | 66.57% |
| 2014 FY | 19.25 Billion KRW | -22.41% |
| 2014 Q2 | 5.94 Billion KRW | 48.16% |
| 2014 Q3 | 7.34 Billion KRW | 23.7% |
| 2013 Q2 | 10.13 Billion KRW | 12.48% |
| 2013 Q3 | 3.25 Billion KRW | -67.9% |
| 2013 Q4 | 2.4 Billion KRW | -26.03% |
| 2013 FY | 24.81 Billion KRW | 2.38% |
| 2013 Q1 | 9.01 Billion KRW | 108.57% |
| 2012 Q4 | 4.32 Billion KRW | -43.47% |
| 2012 FY | 24.23 Billion KRW | -36.72% |
| 2012 Q1 | 6.01 Billion KRW | 0.0% |
| 2012 Q2 | 5.67 Billion KRW | -5.53% |
| 2012 Q3 | 7.64 Billion KRW | 34.58% |
| 2011 Q2 | 9.52 Billion KRW | -26.84% |
| 2011 Q3 | 6.96 Billion KRW | -26.86% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 38.29 Billion KRW | -12.91% |
| 2011 Q1 | 13.02 Billion KRW | 0.0% |
| 2010 Q1 | 11.8 Billion KRW | 0.0% |
| 2010 FY | 43.97 Billion KRW | 24.69% |
| 2010 Q3 | 6.59 Billion KRW | -44.21% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q2 | 11.82 Billion KRW | 0.14% |
| 2009 Q1 | 6.92 Billion KRW | 0.0% |
| 2009 Q2 | 6.57 Billion KRW | -5.11% |
| 2009 Q3 | 10.35 Billion KRW | 57.56% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | 35.26 Billion KRW | 12.9% |
| 2008 Q3 | 7.23 Billion KRW | -12.13% |
| 2008 Q1 | 7.23 Billion KRW | 0.0% |
| 2008 FY | 31.23 Billion KRW | 62.88% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q2 | 8.23 Billion KRW | 13.78% |
| 2007 Q3 | 3.67 Billion KRW | -51.73% |
| 2007 Q2 | 7.61 Billion KRW | 88.19% |
| 2007 Q1 | 4.04 Billion KRW | 0.0% |
| 2007 FY | 19.17 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | 13100.708% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 161.643% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 40.433% |
| HANDOK Inc. | 12.57 Billion KRW | 476.763% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | -2282.554% |
| Yuhan Corporation | 74.56 Billion KRW | 163.561% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | 523.962% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | -162.671% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 121.074% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | 1650.768% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 430.251% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | 8046.375% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | 5017.422% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 275.323% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 13100.708% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | -511.038% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | 1274.932% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 32.248% |
| JW Holdings Corporation | 143.66 Billion KRW | 132.988% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 11.279% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 119.218% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 147.249% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | 784.176% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | 832.378% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | 642.783% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 13100.708% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 197.18% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 135.525% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 147.249% |
| Yuhan Corporation | 74.56 Billion KRW | 163.561% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 326.539% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | 1620.257% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 210.228% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 147.249% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 331.359% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 186.247% |
| CKD Bio Corp. | -20.15 Billion KRW | -135.169% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 247.032% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 287.306% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 245.71% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | -0.0% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 242.977% |
| Boryung Corporation | 68.26 Billion KRW | 169.422% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | -26.391% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 430.251% |
| JW Lifescience Corporation | 32.09 Billion KRW | 247.679% |